A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
Authors:
- Emily Maria PloegEPEmily Maria Ploeg
- Isabel BritschIBIsabel Britsch
- Anne Paulien van WijngaardenAWAnne Paulien van Wijngaarden
- Xiurong KeXKXiurong Ke
- Mark Alexander Johannes Martinus HendriksMHMark Alexander Johannes Martinus Hendriks
- Douwe Freerk SamploniusDSDouwe Freerk Samplonius
- Wijnand HelfrichWHWijnand Helfrich
Open Access
Abstract
PD-1/PD-L1-inhibiting antibodies have shown disappointing efficacy in patients with refractory ovarian cancer (OC). Apparently, OC cells exploit nonoverlapping immunosuppressive mechanisms to evade the immune system. In this respect, the CD73-adenosine inhibitory immune checkpoint is of particular interest, as it rapidly converts pro-inflammatory ATP released from cancer cells to immunosuppressive adenosine (ADO). Moreover, cancer-cell-produced ADO is known to form a highly immunosuppressive extra-tumoral ‘halo’ that chronically inhibits the anticancer activity of various immune effector cells. Thus far, conventional CD73-blocking antibodies such as oleclumab show limited clinical efficacy, probably due to the fact that it indiscriminately binds to and blocks CD73 on a massive surplus of normal cells. To address this issue, we constructed a novel bispecific antibody (bsAb) CD73xEpCAM that inhibits CD73 expressed on the OC cell surface in an EpCAM-directed manner. Importantly, bsAb CD73xEpCAM showed potent capacity to inhibit the CD73 enzyme activity in an EpCAM-directed manner and restore the cytotoxic activity of ADO-suppressed anticancer T cells. Additionally, treatment with bsAb CD73xEpCAM potently inhibited the proliferative capacity of OC cells and enhanced their sensitivity to cisplatin, doxorubicin, 5FU, and ionizing radiation. BsAb CD73xEpCAM may be useful in the development of tumor-directed immunotherapeutic approaches to overcome the CD73-mediated immunosuppression in patients with refractory OC.Keywords
Funding Information
- KWF Kankerbestrijding (11464, 6986)
This publication has 45 references indexed in Scilit:
- Knockdown of EpCAM Enhances the Chemosensitivity of Breast Cancer Cells to 5-fluorouracil by Downregulating the Antiapoptotic Factor Bcl-2PLOS ONE, 2014
- The Roles of CD73 in CancerBioMed Research International, 2014
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbationsMethods, 2014
- Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathwayThe International Journal of Biochemistry & Cell Biology, 2013
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerProceedings of the National Academy of Sciences, 2013
- Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancerIUBMB Life, 2012
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or ErkInternational Journal of Cancer, 2008
- Differential Regulation and Function of CD73, a Glycosyl-Phosphatidylinositol–linked 70-kD Adhesion Molecule, on Lymphocytes and Endothelial CellsJournal of Cell Biology, 1997
- Ecto‐5'‐nucleotidase (CD73) in multidrug‐resistant cell lines generated by doxorubicinInternational Journal of Cancer, 1994